Measurable Residual Disease (MRD) and Circulating Tumour Nucleotides (ct DNA) in cancer drug development
25-26 April 2022, Hybrid Workshop – Amsterdam, NL
On behalf of the Cancer Drug Development Forum and its partners, the program committee would like to welcome you to the CDDF Multi-stakeholder Workshop
“Measurable Residual Disease (MRD) and Circulating Tumour Nucleotides (ctDNA) in Cancer Drug Development” on April 25-26, 2022, in Amsterdam.
The program builds on three previous Multi-Stakeholder Workshops:
- Minimal Residual Disease: Endpoints in Clinical Trials, London, UK, May 13-14, 2014
- Minimal Residual Disease (MM), London, UK, October 18-19, 2017
- Minimal Residual Disease (AML/CLL), London, UK, November 8-9, 2018
The workshop aims to provide updates on new technologies (like ctDNA and next-generation flow cytometry and sequencing) and analyse these from key perspectives (patients, regulatory, academic, payers and industry). Discussions among expert panels and, most importantly, with the participants, will address open questions, next steps and collaborative opportunities.
We are excited about the excellent speakers who have accepted our invitation and incredibly thankful for the support of the regulatory agencies, esp. EMA and FDA, in building the program. Many clinical researchers, pharmaceutical industry representatives, patient advocacy representatives, and regulators, will join us in undoubtedly lively discussions.
Like everyone else, we are watching the SARS-CoV2 pandemic closely. The workshop is currently planned as a ‘hybrid’ meeting, i.e. with on-site and virtual participation. According to the further development of the pandemic, this may be modified. We have intensively invested in video technology and the adaptation of formats to ensure a high-quality experience also for virtual participants.
We are looking forward to the discussions with you, which are at the core of our mission to facilitate oncology drug development.